Purpose The most common long-term complication of joint arthroplasty is aseptic loosening. The proinflammatory cytokines secreted by macrophages are involved in aseptic loosening. Recently, a novel proinflammatory cytokine IL-17C was reported to participate in inflammatory diseases by synergising with proinflammatory cytokines. However, the relationship between IL-17C and the aseptic loosening is unclear. Methods The tissues around aseptic loosened implants were collected during revision surgery and handled by formalin fixation and embedded in paraffin. The presence of IL-17C in the tissues around the aseptic loosened implants was investigated in 12 aseptic loosening patients using immunofluorescence. Results The presence of IL-17C protein in the tissues around aseptic loosened implants was detected by immunofluorescence. There are no statistical differences between optical density of IL-17C in aseptic loosening samples and in rheumatoid arthritis samples (positive control). Conclusions These results suggest the presence of IL-17C in aseptic loosening. Interleukin-17C was related to the inflammation of aseptic loosening, possibly by contributing to the inflammation and osteolysis in the tissues surrounding aseptic loosened implants.
Introduction
Total hip arthroplasty is an effective treatment for irreversible hip disorders, including osteoarthritis, rheumatoid arthritis, congenital hip diseases, and many other end stage joint diseases. The main long-term complication of an initially stable prosthesis is aseptic loosening [1] [2] [3] . Inflammation induced by wear particles of the prosthesis is considered to be the major cause of aseptic loosening [4, 5] with some bacterial components from wounds and intestines are suspected to contribute to the particle-induced inflammation [6] [7] [8] [9] . This inflammation is characterised by macrophage infiltration and proinflammatory cytokine secretion, and the pattern of cytokines consists of tumour necrosis factor alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and interleukin-6 (IL-6) [10] [11] [12] . After phagocytosis or the contact of the implant wear debris with the adhering bacterial components [6] [7] [8] [9] [13] [14] [15] [16] [17] , the nuclear transcription factor-kappa B (NFkappa B) of the macrophage is activated, and the macrophages express the above mentioned proinflammatory cytokines in response [11, 12, 18] . These proinflammatory cytokines disrupt the local balance of osteogenesis and osteolysis through the proliferation of osteoclasts and the inhibition of osteoblasts [12, [19] [20] [21] .
Interleukin-17C (IL-17C) is a recently identified member of the IL-17 superfamily [22] . Unlike other members of the IL-17 superfamily, it is secreted by a wide spectrum of cells
including macrophages, rather than T cells [23] [24] [25] [26] [27] . IL-17C was demonstrated to have strong proinflammatory effects [26] . Normal human tissues barely express IL-17C [22] . However, the expression of IL-17C has been documented in some diseases that are usually characterised by inflammation with macrophage infiltration. For example, the expression of IL-17C has been identified in a wide spectrum of sources including CD11b + MHC class II macrophages, CD11c + MHC class II dendritic cells, lung tissues of mouse mycoplasma pneumonia, and the paws of the mouse collagen-induced arthritis model. And IL-17C was found to contribute to the exacerbation of the inflammation by increasing TNF-alpha and IL-1beta expression [22, 26] . In humans, IL-17C has been identified to be expressed in the synovial cells of rheumatoid arthritis patients [28] , in psoriatic skin [24, 29] , and in cultured human keratinocytes stimulated with TNF-alpha [23] . However, little is known about the expression of IL-17C in other diseases characterised by macrophage infiltration, such as the aseptic loosening after joint arthroplasty. We postulated that the proinflammatory cytokine IL-17C might be associated with wear debris-activated macrophages in the interface membrane surrounding aseptic loosened implants. To the best of our knowledge, no reports have previously demonstrated this. Thus, the aim of this study was to investigate the presence of IL-17C in the interface membrane surrounding the aseptic loosened implants after total joint arthroplasty, compared to the known IL-17C-positive rheumatoid synovial membrane [26, 28] .
Methods

Ethics statement
The patients were fully aware of the project and gave written informed consent. The project was approved by the ethical committee of Sun Yat-sen University of Medicine.
Patients and samples
Patients who were suffering from an episode of clinical aseptic loosening were selected from all patients in the joint department of the First Affiliated Hospital of Sun Yat-sen University and the Huangpu Joint Centre from September 2008 to September 2009. The exclusion criteria included repeat revision surgery, and the presence of rheumatoid arthritis, ankylosis spondylitis, systemic lupus erythematous, infection or any other conditions that might affect the local or systemic immune system. Twelve cases were finally included. The interface membranes surrounding the loosened parts of the implants (femoral or acetabular) were taken for biopsy during the revision operations. ESR preoperative erythrocyte sedimentation rate (mm/h), CRP preoperative C-reactive protein levels (mg/l), RF preoperative rheumatoid factor (U/ml)
All the patients were clinically diagnosed as rheumatoid arthritis according to the manifestation, radiology and pathology a Location where synovial membranes were dissected as clinical samples
Since the expression of IL-17C in rheumatoid synovium has been demonstrated [26, 28] , an additional five cases of rheumatoid arthritis were included as positive controls and the synovium was taken for biopsy during the primary arthroplasty. Normal goat and mouse immunoglobulin serum fractions were used as a negative control for IL-17C and CD68 staining, respectively.
Clinical samples were immediately fixed in 30 % formalin for 24-48 hours, followed by dehydration in ethanol, clearing in xylene, embedding in paraffin, and storage at room temperature.
Immunofluorescence analysis
The immunofluorescence staining protocol was performed by referring to prior reports [30, 31] . Four-μm thick paraffin sections were cut, deparaffinised and rehydrated using routine methods. The antigen retrieval was performed by maintaining the sections at a moderate boil in a citric acid buffer solution (pH 6.0). Non-specific antigen binding sites were blocked by incubation with 10 % normal rabbit serum for 40 minutes before applying the primary antibodies (goat anti-human IL-17C, 20 μg/ml, R&D, AF1234; mouse anti-human CD68, 20 μg/ml, R&D MAB20401; 1 % normal rabbit serum). Then the mixture was incubated overnight in a moist 4°C environment. Next, the slides were washed five times with PBS for five minutes, and the secondary antibodies were applied (rabbit anti-goat CY3-labelled, 1:100, Boster SA1076; rabbit antimouse FITC-labelled, 1:50, Boster). The sections were counter-stained with DAPI.
The haematoxylin and eosin staining Five-μm paraffin sections were cut consecutively, followed by deparaffinising and rehydrating. Sections were subjected to the standard haematoxylin and eosin staining method.
Microscopy
Within 24 hours, both the immunofluorescence staining sections and the haematoxylin and eosin staining sections were examined and photographed under microscopy (Axio Imager Z1b, ZEISS). Five random high power visual fields were independently selected by two observers for each section, and the optical density was calculated.
Statistical analysis
The results are expressed as the mean and standard error (mean ± SE). Differences between groups were analysed using analysis of variance (ANOVA) with PSS 13.0. A P value of <0.05 was regarded as statistically significant. 
Results
Preoperative data on clinical samples
Preoperative data of the 12 aseptic loosening cases are listed in Table 1 , and the data of the five rheumatoid arthritis patients are listed in Table 2 .
Histology
In aseptic loosening samples, a great amount of monocyte/-macrophages could be viewed in the section, infiltrating the connective tissue stroma (Fig. 1a) . In other areas of the section, loose or tight connective tissues were less infiltrated with proinflammatory cells. In the rheumatoid arthritis samples, even more monocytes were infiltrating the rheumatoid synovial membranes compared to the aseptic loosening samples (Fig. 1b) .
IL-17C immunofluorescence
Because of the high expression of IL-17C in the synovium of rheumatoid arthritis identified previously, we chose the rheumatoid arthritis clinical samples as the positive control [26, 28] . Compared to the negative control group, the statistically greater staining in the rheumatoid synovial membrane confirmed the previous reports [26, 28] and proved the rheumatoid synovial membrane was a good positive control. The very mild staining in the negative control and the statistically lower presence of IL-17C compared to the rheumatoid synovial membrane suggested a valid negative control group.
The presence of IL-17C was present in the cytoplasm of aseptic loosening samples as well as in the synovium of rheumatoid arthritis, compared to the negative control group (Fig. 2a, b and c) . The "vascular sleeve" structures were significantly stained (Fig. 3a) , suggesting the association of IL-17C with inflammation and vessel responses. The multinucleate giant cells scattered in the section were also stained, which were supposed to be fused by macrophages (Fig. 3b) .
To further investigate the source of IL-17C in the tissues around aseptic loosened implants, we examined the colocalisation of IL-17C with CD68 using immunofluorescence double staining. The results suggested that 55.32±10.11 % of CD68+ macrophages were colocalised with IL-17C, implying IL-17C was expressed by macrophages (Fig. 4a, b and c) .
The semiquantitative analysis of the immunofluorescence revealed that the presence of IL-17C in the tissues around aseptic loosened implants was greater compared to the negative control group (in the mean optical density, 794.81±41. Discussion IL-17C is a novel proinflammatory cytokine that is involved in many inflammatory diseases, including rheumatoid [28] and psoriatic conditions [24, 29] and conditions under the compressive force [25] . Interleukin-17C has also been proven to originate from several sources, including human keratinocytes [23] , MC3T3-E1 cells [25] [26] , synovial fluid mononuclear cells of rheumatoid arthritis patients [28] and Fig. 5 The semiquantitative analysis for the aseptic loosening, rheumatoid arthritis and the negative control groups. Semiquantitative analysis of the immunofluorescence was performed for the samples of the aseptic loosening, rheumatoid arthritis and the negative control groups. The optical density was calculated and compared. The differences between aseptic loosening and the negative control group and between rheumatoid arthritis and the negative control group were significant (both P<0.001), whereas the difference between aseptic loosening and rheumatoid arthritis was not significant (P>0.05) Fig. 6 A hypothesis of a positive feedback loop between the expression of IL-17C and the activation of macrophages. The expression of IL-17C in macrophages was identified [23, 26] and further supported in this study. And the direct proinflammatory effect of IL-17C on macrophages was also identified [22, 26, 34] . Taken together, macrophages activated by wear particles and bacterial components secrete IL-17C, and IL-17C in turn enhances the activation of macrophages in an autocrine manner [34] , thus forming a positive feedback loop the Mycoplasma pneumonia infected mouse lung tissues, but not from CD4 + T cells [26, 27] . This study demonstrates for the first time that IL-17C is present in the tissues around aseptic loosened implants. Interleukin-17C has been proven to be a strong proinflammatory cytokine and contributes to exacerbation of arthritic paws of collagen-induced arthritic mice [26] . Interleukin-17C stimulates the release of TNF-alpha and IL-1beta from the monocyte cell line, THP-1 [22] . The wear debris and bacterial components-induced aseptic inflammation and proinflammatory cytokines (TNF-alpha and IL-1beta) have been shown to play an important role in the osteolysis and the aseptic loosening progression [11, 19, 32, 33] . Thus, the presence of IL-17C in the tissues around aseptic loosened implants implies a role of IL-17C in the osteolysis and progression of aseptic loosening, possibly by contributing to the enhanced expression of TNF-alpha and IL-1beta, or the direct effect of IL-17C on the osteolysis. In addition, the vascular sleeves formed by IL-17C positive cells around the small vessels imply the possible relation of IL-17C and the vessel response, suggesting a potential role of IL-17C in the inflammation of aseptic loosening.
Macrophages have been proven to be the most prevalent cells, accounting for about 70 % of all cells in tissues around aseptic loosened implants. The extensive presence of IL-17C in tissues around aseptic loosened implants indicates the possible relationship of IL-17C and macrophages. And according to our experiment, IL-17C is present in the cytoplasm, especially in the cytoplasm of multinucleate giant cells, suggesting that IL-17C is apt to be expressed by macrophages. The results of colocalisation with IL-17C and CD68 antibodies suggest that IL-17C is expressed by CD68 + macrophages in aseptic loosening samples. Previous works have also supported the view that one of the origins of IL-17C was macrophages [26] .
A positive feedback loop formed by the expression of IL-17C and the activation of epithelial cells has been proven to regulate the innate immune function [34] (Fig. 6 ). Considering macrophages acting as both the origin and the target of IL-17C, IL-17C might contribute to the regulation of inflammation and innate immune function in an autocrine manner similar to the previous report (Fig. 5) [34] .
The shortage of the immunofluorescence study lies in the fact that the possible expression of IL-17C in non inflamed tissues around stable implants is not excluded. In conclusion, our study demonstrates the presence of IL-17C in the tissues around aseptic loosened implants, implying the involvement of a new cytokine in the inflammation of aseptic loosening.
